Nonproliferative retinopathy - Biotech, Pharma and Life Science Channel

20:23 EDT 20th August 2014 | BioPortfolio

PubMed Articles [298 Associated PubMed Articles listed on BioPortfolio]

Genetics of Diabetic Retinopathy.

Diabetic retinopathy (DR) is a polygenic disorder. Twin studies and familial aggregation studies have documented clear familial clustering. Heritability has been estimated to be as high as 27 % for a...

Development of an Experimental Model of Proliferative Retinopathy by Intravitreal Injection of VEGF165.

Abstract Purpose: To develop an experimental model of proliferative retinopathy by intravitreal injection of vascular endothelial growth factor 165 (VEGF165) in pigmented rabbits. Methods: A prospecti...

Pharmacokinetics and local safety profile of propranolol eye drops in rabbits.

Background.Oral propranolol, a non-selective ß-blocker, is able to reduce the progression of retinopathy of prematurity in newborns, but it appeared unsafe. This study aimed to find, in rabbits, a pr...

Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases.

Retinal neurodegenerative diseases like age-related macular degeneration, glaucoma, diabetic retinopathy and retinitis pigmentosa each have a different etiology and pathogenesis. However, at the cellu...

Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity.

Abstract Purpose: To evaluate the two-year follow-up of patients with type 1 retinopathy of prematurity (ROP) who received intravitreal bevacizumab (IVB) as adjunctive treatment. Materials and methods...

Notch signaling functions in retinal pericyte survival.

Purpose: Pericytes, the vascular cells that constitute the outer layer of capillaries, have been shown to play a crucial role in vascular development and stability. Loss of pericytes precedes endothel...

Elevated Soluble VEGF Receptor sFlt-1 Correlates with Endothelial Injury in IgA Nephropathy.

Endothelial injury, which may present clinically as hypertension, proteinuria and increased von Willebrand Factor (vWF) level, is a common manifestation in IgA nephropathy (IgAN). However, causal fact...

Clock genes and behavioral responses to light are altered in a mouse model of diabetic retinopathy.

There is increasing evidence that melanopsin-expressing ganglion cells (ipRGCs) are altered in retinal pathologies. Using a streptozotocin-induced (STZ) model of diabetes, we investigated the impact o...

SURGICAL OUTCOMES OF FLORID DIABETIC RETINOPATHY TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR.

To evaluate the effectiveness of vitreoretinal surgery combined with antivascular endothelial growth factor therapy to treat florid diabetic retinopathy, a rare and severe form of diabetic retinopathy...

Epigenetic modifications of Nrf2-mediated glutamate cysteine ligase: Implications in the development of diabetic retinopathy and in the metabolic memory phenomenon associated with its continued progression.

Diabetes increases oxidative stress in the retina and decreases the levels of intracellular antioxidant, GSH. Transcriptional factor Nrf2 regulates the expression of Gclc, the enzyme important in the...

News Articles [107 Associated News Articles listed on BioPortfolio]

KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema

SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company wit...

Genentech files sBLA for Lucentis for diabetic retinopathy

Genentech, the biotech subsidiary of Swiss pharma major Roche, has submitted a supplemental Biologics License Application (sBLA) with the US Food and Drug Administration for Lucentis (ranibizumab inje...

Roche/Genentech eye US diabetic retinopathy market for Lucentis

Diabetic retinopathy is the leading cause of new cases of blindness in working-age Americans.

Genentech Submits sBLA for Diabetic Retinopathy Drug

Genentech, a member of the Roche Group, announced that the company has submitted a supplemental Biologics License Application (sBLA) for Lucentis (ranibizumab injection) to the U.S. Food and Drug Admi...

Genentech submits sBLA for Lucentis for diabetic retinopathy

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) submitted an sBLA to FDA to expand the label for Lucentis ranibizumab to include diabetic retinopathy. The humanized mAb fragment against VEGF-A...

Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a supplemental Biologics License Application (sBLA) for Lucenti...

Targazyme receives grant to develop cell therapy for retinopathy

The National Eye Institute has awarded a grant to Targazyme to support the development of a cell-based therapy for diabetes-r -More- 

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes Eye advance online publication, August 8 2014. doi:10.1038/eye.2014.172 Autho...

Complete analysis of retinopathy screening devices in the US market

Reportbuyer.com has added a new market research report: U.S. Market and Survey for Retinopathy Screening Devices

2 Millionth Image Processed by Telemedicine Diabetic Retinopathy Screening Programs Supported by Estenda Solutions, Inc.

The telemedicine diabetic retinopathy (DR) screening programs supported by Estenda Solutions, Inc. recently processed the 2-millionth image. Conshohocken, PA (PRWEB) August 05, 2014 The telemedicine...

Events [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to de...

Acucela Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye di...

Acucela

Acucela Inc. (www.acucela.com) is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for...

NormOxys, Inc.

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen def...

Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By...

Clinical Trials [166 Associated Clinical Trials listed on BioPortfolio]

Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema

This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficia...

Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity

To determine the safety and efficacy of trans-scleral cryotherapy of the peripheral retina in certain low birth-weight infants with retinopathy of prematurity (ROP) for reducing blindness...

Early Treatment Diabetic Retinopathy Study (ETDRS)

To evaluate the effectiveness of both argon laser photocoagulation and aspirin therapy in delaying or preventing progression of early diabetic retinopathy to more severe stages of visual l...

Diabetic Retinopathy Vitrectomy Study (DRVS)

To compare two therapies, early vitrectomy and conventional management, for recent severe vitreous hemorrhage secondary to diabetic retinopathy. Conventional management includes vitrectom...

Diabetic Retinopathy and Visual Function Study

The purpose of this study is to evaluate possible mechanisms of central visual loss in patients with diabetes mellitus. The visual loss of interest to be investigated is that associated w...

Blood Factors and Diabetic Retinopathy

This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy. Patients age 10 years and older with diabetes mellitus and diabeti...

Retinal Arteriolar Abnormalities and CV Mortality

To determine whether retinal arteriolar changes (generalized narrowing, focal narrowing and arterio-venous nicking) and retinopathy were associated with 10-year stroke-and ischemic heart...

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.

Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials

OBJECTIVE: This study is being conducted by the Type 1 Diabetes TrialNet Study Group, funded by the National Institutes of Health, in collaboration with the European C-Peptide Group. The...

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening...

Medical and Biotech [MESH] Definitions

A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)

Degenerative changes to the RETINA due to HYPERTENSION.

A drug used to reduce hemorrhage in diabetic retinopathy.

Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.

Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Search BioPortfolio:
Advertisement
Advertisement
review and buy Nonproliferative retinopathy market research data and corporate reports here

Channels Quicklinks